Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Université Laval

$37,000.00

Chemogenetic control of liver metabolism

EF 2023-24

Résumé
Hepatic glucose production (HGP) is the result of coordinated biochemical processes by which glycogen storage are catabolized to generate glucose (glycogenolysis), or glucose is produced from non-carbohydrate carbon substrates (gluconeogenesis). These processes are regulated by many G protein coupled receptors (GPCRs) expressed at the surface of the hepatocytes. As their names imply, GPCRs interact with G proteins located in the plasma membrane. When a ligand binds to the GPCR, it causes a conformational change that triggers the interaction between the GPCR and a nearby G protein. However, the downstream signaling events mediating the effects of GPCR activation on HPG are still misunderstood because of the lack of appropriate tools to selectively stimulate G proteins acutely. Here, I propose to harness the power of chemogenetics to selectively manipulate GPCR signaling in hepatocytes, as a mean of defining the complex biochemical reactions leading to HGP. Chemical genetics (chemogenetics) is an approach use to genetically engineer receptors that interact with previously unrecognized small molecule chemical actuators. This approach has been used to create modified GPCRs, called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). Originally developed to control neuronal activity, DREADDs are emerging as key tools for selective pharmacological control of GPCR signaling in any cell type or organ. Recently, I reported the generation of a novel chemogenetic approach allowing acute stimulation of GsPCR and GiPCR signaling in adipocytes. This innovative model revealed important, previously unappreciated complex interactions of GPCR signaling in adipose tissue and demonstrated the usefulness of chemogenetic technology to better understand organ functions. I propose to combine state-of-the-art metabolic flux techniques with chemogenetics models to better understand the mechanisms mediating HGP. In particular, I propose to use chemogenetics to dissect two important metabolic pathways for HGP, namely glycogenolysis and gluconeogenesis in vitro (primary hepatocytes), ex vivo (perfused livers) and in vivo. Building on my previous work and expertise on liver metabolism and chemogenetic technology, this program aims to: 1) determine the sex-dependent mechanisms by which chemogenetic stimulation of liver GqPCR stimulate HGP; 2) evaluate how GqPCR signaling affects metabolic flux independent of changes in peripheral hormones in a perfused mouse liver model; 3) define the molecular cascade leading to HGP in primary hepatocytes. This Discovery Grant will define complex previously unknown mechanisms mediating HGP. Understanding this biology will provide a framework to better understand how different systems directly regulates liver metabolism. This program will also provide a powerful and sought after scientific and technical skill set for my students and the field to understand other regulatory factors involved in peripheral metabolism.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2020-05508
Name nom
Caron, Alexandre
Department département
Faculté de pharmacie
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2020
Award amount
37000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5408
Research subject group en
Biochemistry
Research subject group fr
Metabolism
Research subject en
Biochimie
Research subject fr
Métabolisme
Application title
Chemogenetic control of liver metabolism
Keyword
Calcium; Chemogenetic; DREADD; Glucagon; Glucose; Glycerol; Glycogen; G protein coupled receptor; Liver; Primary hepatocytes
Application summary
Hepatic glucose production (HGP) is the result of coordinated biochemical processes by which glycogen storage are catabolized to generate glucose (glycogenolysis), or glucose is produced from non-carbohydrate carbon substrates (gluconeogenesis). These processes are regulated by many G protein coupled receptors (GPCRs) expressed at the surface of the hepatocytes. As their names imply, GPCRs interact with G proteins located in the plasma membrane. When a ligand binds to the GPCR, it causes a conformational change that triggers the interaction between the GPCR and a nearby G protein. However, the downstream signaling events mediating the effects of GPCR activation on HPG are still misunderstood because of the lack of appropriate tools to selectively stimulate G proteins acutely. Here, I propose to harness the power of chemogenetics to selectively manipulate GPCR signaling in hepatocytes, as a mean of defining the complex biochemical reactions leading to HGP. Chemical genetics (chemogenetics) is an approach use to genetically engineer receptors that interact with previously unrecognized small molecule chemical actuators. This approach has been used to create modified GPCRs, called Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). Originally developed to control neuronal activity, DREADDs are emerging as key tools for selective pharmacological control of GPCR signaling in any cell type or organ. Recently, I reported the generation of a novel chemogenetic approach allowing acute stimulation of GsPCR and GiPCR signaling in adipocytes. This innovative model revealed important, previously unappreciated complex interactions of GPCR signaling in adipose tissue and demonstrated the usefulness of chemogenetic technology to better understand organ functions. I propose to combine state-of-the-art metabolic flux techniques with chemogenetics models to better understand the mechanisms mediating HGP. In particular, I propose to use chemogenetics to dissect two important metabolic pathways for HGP, namely glycogenolysis and gluconeogenesis in vitro (primary hepatocytes), ex vivo (perfused livers) and in vivo. Building on my previous work and expertise on liver metabolism and chemogenetic technology, this program aims to: 1) determine the sex-dependent mechanisms by which chemogenetic stimulation of liver GqPCR stimulate HGP; 2) evaluate how GqPCR signaling affects metabolic flux independent of changes in peripheral hormones in a perfused mouse liver model; 3) define the molecular cascade leading to HGP in primary hepatocytes. This Discovery Grant will define complex previously unknown mechanisms mediating HGP. Understanding this biology will provide a framework to better understand how different systems directly regulates liver metabolism. This program will also provide a powerful and sought after scientific and technical skill set for my students and the field to understand other regulatory factors involved in peripheral metabolism.